Clinical trials: Patients With Major Depressive Disorder
Major Depressive Disorder
A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder
The purpose of this study is to assess the effect and safety of AZD6765 in patients with major depressive disorder who exhibit inadequate response to antidepressants.
- Trial name
- NCT01482221
- Testing
- AZD6765 iv
- Where
- 44 sites in United States, Chile and 2 more
- Volunteers
- 542 people
- Sponsor
- AstraZeneca
Depression - Major Depressive Disorder
Effectiveness of Behavioral Activation Group Therapy for Patients With Depression at the Community in Thanh Hoa
This study aimed to evaluate whether the 8-week BA group therapy delivered at commune health stations (CHSs) improves depressive symptom severity, psychological distress, behavioral activation, resilient coping, and…
- Trial name
- not yet (NCT07527312)
- Testing
- Behaviral activation group therapy
- Where
- Vietnam
- Volunteers
- 242 people, healthy volunteers welcome
- Sponsor
- Hanoi Medical University
Major Depressive Episode
Predict MDE Outcomes After MST
This trial attempts to explore the treatment outcome of magnetic seizure therapy (MST) for major depressive episode. Half of the participants will receive MST, while the other half will receive electroconvulsive therapy (ECT).
- Trial name
- NCT03841019
- Testing
- Magpro X100 + Option, ThymatronSystem Ⅳ Electroconvulsive System
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanghai Mental Health Center
Major Depressive Disorder
Citalopram Titration in Early Non-responder Patients With Major Depressive Disorders
Major depressive disorder is a common mental disorder and the leading cause of disability worldwide. According to the Canadian Network for Mood and Anxiety Treatment, early improvement following an antidepressant treatment is…
- Trial name
- CRY-MOOD (NCT03899285)
- Testing
- Citalopram 20mg or 40 mg (phase 2)
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Major Depressive Disorder
6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder
This is a 6-week study treatment to evaluate the safety and effectiveness of AZD2066 in patients with major depressive disorder.
- Trial name
- NCT01145755
- Testing
- AZD2066, Duloxetine
- Where
- 13 sites in United States
- Volunteers
- 131 people
- Sponsor
- AstraZeneca
Depression, Unipolar
Pulsed Electro Magnetic Fields (PEMF) in Depression
PEMF (Pulsed Electro Magnetic Fields) therapy has been used to stimulate bone repair in non-union since the 1970s. This is an accepted use, which has been approved by the Food and Drug Administration in the US.
- Trial name
- PEMF (NCT03556735)
- Testing
- Treatment with PEMF equipment
- Where
- Denmark
- Volunteers
- 59 people
- Sponsor
- University of Southern Denmark
Depression, Depressive Disorder
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of TNX-601 ER monotherapy versus placebo in patients with Major Depressive Disorder (MDD).
- Conditions
- Depression, Depressive Disorder, Depressive Symptoms, Depressive Disorder, Major
- Trial name
- UPLIFT (NCT05686408)
- Testing
- TNX-601 ER
- Where
- 27 sites in United States
- Volunteers
- 132 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Major Depressive Disorder, Depression
Evaluation of Efficacy of Lycium Barbarum Polysaccharide in Patients With Major Depressive Disorder
Lycium barbarum, a traditional Chinese herbal medicine, is a commonly used herb in the traditional Chinese pharmacopoeia. Its main active ingredient, lycium barbarum polysaccharide (LBP), is reported to have neuroprotective…
- Conditions
- Major Depressive Disorder, Depression, Depressive Disorder
- Trial name
- NCT04124276
- Testing
- Lycium barbarum polysaccharide
- Where
- China
- Volunteers
- 284 people
- Sponsor
- Guangzhou Psychiatric Hospital
Depression
p11 Protein Levels in Patients With Major Depressive Disorder Treated With Citalopram
This study will compare levels of p11 protein in people with and without major depressive disorder (MDD) and examine if p11 levels in patients are affected by treatment with citalopram (Celexa).
- Trial name
- NCT00697268
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder
Open-label, Flexible-dose Study of Vortioxetine in Patients With Depression in India
The purpose of this study is to evaluate the safety and tolerability of flexible doses of vortioxetine (5 - 20 mg/day) over a period of 12 weeks in patients with depression in India
- Trial name
- NCT04288895
- Testing
- Vortioxetine
- Where
- 24 sites in India
- Volunteers
- 400 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorders
N-Acetyl Cysteine Supplementation in Therapy Refractory Major Depressive Disorders
The aim of this study is to evaluate the efficacy of N-acetylcysteine (NAC) add-on to antidepressant medication in treating patients who do not relieve during standard antidepressant treatment for 6 weeks at least.
- Trial name
- NCT02972398
- Testing
- N-acetylcysteine
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tianjin Anding Hospital
Major Depressive Disorder, Dementia
Vortioxetine in Patients With Depression and Early Dementia
This study evaluates the effectiveness of vortioxetine on depressive symptoms in patients with depression and early dementia
- Trial name
- MEMORY (NCT04294654)
- Testing
- Vortioxetine
- Where
- 24 sites in Estonia, France and 4 more
- Volunteers
- 82 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder
The purpose of this study is to assess the long-term safety, tolerability and efficacy of oral OPC-34712 as adjunctive therapy in the treatment of adult patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01447576
- Testing
- ADT, OPC-34712
- Where
- 32 sites in United States
- Volunteers
- 1,036 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Disorder, Major
Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)
The purpose of this study is to assess the efficacy, safety and tolerability of GW679769 patients with Major depressive Disorder (MDD).
- Trial name
- NCT00413023
- Testing
- GW679769
- Where
- 39 sites in Argentina, Belgium and 9 more
- Volunteers
- 348 people
- Sponsor
- GlaxoSmithKline
Depressive Disorder, Major, Adult Attention Deficit Hyperactivity Disorder
Clinical and Suicidal Features of Urban, Turkish Middle Age Depressive Patients With Comorbid ADHD
In the presence of attention deficit hyperactivity disorder (ADHD) together with additional psychiatric diseases, the treatment process and prognosis of both ADHD and psychiatric comorbidity are adversely affected.
- Conditions
- Depressive Disorder, Major, Adult Attention Deficit Hyperactivity Disorder, Suicide
- Trial name
- NCT03721588
- Testing
- Clinical interviews, psychometric scales were applied.
- Volunteers
- 96 people
- Sponsor
- Bozyaka Training and Research Hospital
Major Depression
Electroconvulsive Therapy (ECT) for Elderly Patients With Major Depression
ECT (electroconvulsive therapy) is mostly given to patients between the age of 60 - 85 years. There is limited evidence on the efficacy and cognitive side-effects of right unilateral (RU) and bifrontal (BF) electrode positions…
- Trial name
- NCT01559324
- Testing
- ECT
- Where
- Norway
- Volunteers
- 92 people
- Sponsor
- Diakonhjemmet Hospital
Major Depressive Disorder (MDD)
Acceptance and Committment Therapy Combined With Ketamine in Difficult-to-Treat Depression.
Ketamine is often used to treat depression where standard treatments have failed. Yet, even with ketamine, depression can persist and make it difficult to keep up with life.
- Trial name
- K-ACT (NCT07906496)
- Testing
- K-ACT Intervention
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University of British Columbia
Major Depressive Disorder
Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults
The purpose of this Venlafaxine-referenced study is to evaluate the efficacy, safety and tolerability of two fixed doses of Vortioxetine in the acute treatment of Major Depressive Disorder (MDD).
- Trial name
- NCT00839423
- Testing
- Vortioxetine (Lu AA21004), Venlafaxine XL
- Volunteers
- 426 people
- Sponsor
- H. Lundbeck A/S
Malignant Brain Tumors
PRESENCE Project: An Early Palliative Care Intervention in Brain Tumors
The purpose of this pilot study is to investigate the feasibility of an early palliative care intervention (PRESENCE: Providing Resources Education, Support, and Enabling New brain tumor patients to Cope Effectively) and the…
- Trial name
- NCT01652768
- Testing
- Research Questionnaires, Palliative Care Team, Educational Information Session for Patients and Caregivers
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Case Comprehensive Cancer Center
Depressive Disorder, Major
Mindfulness Based Cognitive Therapy and Antidepressant Medication in Recurrent Depression
The purpose of this study is to investigate the (cost)effectiveness of mindfulness based cognitive therapy (MBCT) compared to that of antidepressant medication, and its combination with regard to the prevention of relapse or…
- Trial name
- NCT00928980
- Testing
- Mindfulness Based Cognitive Therapy, Optimal Medical Care
- Where
- 13 sites in Netherlands
- Volunteers
- 317 people
- Sponsor
- Radboud University Medical Center